Press
Releases

Press Releases

March 12, 2021
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Md. and BASEL, Switzerland , March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today
March 8, 2021
Altimmune to Present at Upcoming Conferences
GAITHERSBURG, Md. , March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference , being held Mar 9-10,
February 22, 2021
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
GAITHERSBURG, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25 th , 2021. Altimmune management will host a conference call for
February 17, 2021
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week GAITHERSBURG, Md. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S.
 

Investor Contacts

Stacey Jurchison
Altimmune

Email: sjurchison@altimmune.com

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe